The subgroup analysis of 104 patients with aBTC treated with pembrolizumab revealed an RR of 5.8% with a median PFS of 2 months and a mOS of 9.1 months, regardless of PD-L1 positivity (membranous PD-L1 expression in ≥1% of tumours and associated inflammatory cells or positive staining in stroma).52 Consistent with other studies, pembrolizumab showed durable antitumour activity among the few responsive patients. Here, CD274 is linked to neoplasm.